surgoncoКреативная хирургия и онкологияCreative surgery and oncology2076-30932307-0501Башкирский государственный медицинский университет10.24060/2076-3093-2020-10-4-311-318surgonco-535Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWSМикро-РНК как биомаркеры и терапевтические мишени при медуллобластомахMicroRNAs as Biomarkers and Therapeutic Targets for Medulloblastomashttps://orcid.org/0000-0002-6149-5460БейлерлиО. А.BeylerliO. A.obeylerli@mail.ruhttps://orcid.org/0000-0002-4965-0835ГареевИ. Ф.GareevI. F.
Cand. Sci. (Med.), Department of Oncology with Courses of Oncology and Pathological Anatomy for AdvancedProfessional Education
Ufa
https://orcid.org/0000-0001-7249-0713АлышовА. Б.AlyshovA. B.
Уфа
Ufa
https://orcid.org/0000-0003-2444-9104КудряшовВ. В.KudriashovV. V.Башкирский государственный медицинский университетРоссияBashkir State Medical UniversityRussian FederationРеспубликанский кардиологический центрРоссияRepublican Cardiology CentreRussian FederationЗападный китайский госпиталь Сычуаньского университетаКитайWest China Hospital of Sichuan UniversityChina202030122020104311318Copyright © Бейлерли О.А., Гареев И.Ф., Алышов А.Б., Кудряшов В.В., 20202020Бейлерли О.А., Гареев И.Ф., Алышов А.Б., Кудряшов В.В.Beylerli O.A., Gareev I.F., Alyshov A.B., Kudriashov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgonco.ru/jour/article/view/535медуллобластомамикроРНКновообразования центральной нервной системыгенетическая гетерогенностьбиомаркерыканцерогенезгены супрессорытерапевтические мишениmedulloblastomamicroRNAcentral nervous system neoplasmsgenetic heterogeneitybiomarkerscarcinogenesissuppressor genestherapeutic targetsReferencesWang J., Garancher A., Ramaswamy V., Wechsler-Reya R.J. Medulloblastoma: from molecular subgroups to molecular targeted therapies. Annu Rev Neurosci. 2018;41:207–32. DOI: 10.1146/annurev-neuro-070815-013838Wang J., Garancher A., Ramaswamy V., Wechsler-Reya R.J. Medulloblastoma: from molecular subgroups to molecular targeted therapies. Annu Rev Neurosci. 2018;41:207–32. DOI: 10.1146/annurev-neuro-070815-013838Udaka Y.T., Packer R.J. Pediatric brain tumors. Neurol Clin. 2018;36(3):533–56. DOI: 10.1016/j.ncl.2018.04.009Udaka Y.T., Packer R.J. Pediatric brain tumors. Neurol Clin. 2018;36(3):533–56. DOI: 10.1016/j.ncl.2018.04.009Chamdine O., Elhawary G.A.S., Alfaar A.S., Qaddoumi I. The incidence of brainstem primitive neuroectodermal tumors of childhood based on SEER data. Childs Nerv Syst. 2018;34(3):431–9. DOI: 10.1007/s00381-017-3687-4Chamdine O., Elhawary G.A.S., Alfaar A.S., Qaddoumi I. The incidence of brainstem primitive neuroectodermal tumors of childhood based on SEER data. Childs Nerv Syst. 2018;34(3):431–9. DOI: 10.1007/s00381-017-3687-4Chevignard M., Câmara-Costa H., Doz F, Dellatolas G. Core deficits and quality of survival after childhood medulloblastoma: a review. Neurooncol Pract. 2017;4(2):82–97. DOI: 10.1093/nop/npw013Chevignard M., Câmara-Costa H., Doz F, Dellatolas G. Core deficits and quality of survival after childhood medulloblastoma: a review. Neurooncol Pract. 2017;4(2):82–97. DOI: 10.1093/nop/npw013Srivastava V.K., Nalbantoglu J. The cellular and developmental biology of medulloblastoma: current perspectives on experimental therapeutics. Cancer Biol Ther. 2010;9:843–52. DOI: 10.4161/cbt.9.11.11785Srivastava V.K., Nalbantoglu J. The cellular and developmental biology of medulloblastoma: current perspectives on experimental therapeutics. Cancer Biol Ther. 2010;9:843–52. DOI: 10.4161/cbt.9.11.11785Kim W., Choy W., Dye J., Nagasawa D., Safaee M., Fong B., et al. The tumor biology and molecular characteristics of medulloblastoma identifying prognostic factors associated with survival outcomes and prognosis. J Clin Neurosci. 2011;18:886–90. DOI: 10.1016/j.jocn.2011.01.001Kim W., Choy W., Dye J., Nagasawa D., Safaee M., Fong B., et al. The tumor biology and molecular characteristics of medulloblastoma identifying prognostic factors associated with survival outcomes and prognosis. J Clin Neurosci. 2011;18:886–90. DOI: 10.1016/j.jocn.2011.01.001Тармаев А.А., Бейлерли О.А. МикроРНК как перспективные биомаркеры при раке. Вестник Северо- Западного государственного медицинского университета им. И.И. Мечникова. 2019;11(3):5–12. DOI: 10.17816/mechnikov20191135-12Tarmaev A.A., Beylerli O.A. MiRNAs as promising biomarkers in cancer. HERALD of North-Western State Medical University named after I.I. Mechnikov. 2019;11(3):5–12 (In Russ.). DOI: 10.17816/mechnikov20191135-12Бейлерли О.А., Гареев И.Ф. Микро-РНК как терапевтические мишени при нейробластомах. Инновационная медицина Кубани. 2019;(4):66–71. DOI: 10.35401/2500-0268-2019-16-4-66-71Beylerli O.A., Gareev I.F. Micro-RNP as therapeutic targets for neuroblastomas. Innovative medicine of Kuban. 2019;(4):66–71 (In Russ.). DOI: 10.35401/2500-0268-2019-16-4-66-71Гареев И.Ф., Бейлерли О.А. Изучение роли микроРНК при аденоме гипофиза. Успехи молекулярной онкологии. 2018;5(2):8–15.Gareev I.F., Beylerli O.A. A study of the role of microRNA in pituitary adenoma. Advances in Molecular Oncology. 2018;5(2):8–15 (In Russ.).Zhan S., Wang Y., Chen X. RNA virus-encoded microRNAs: biogenesis, functions and perspectives on application. ExRNA. 2020;2(1):15. DOI: 10.1186/s41544-020-00056-zZhan S., Wang Y., Chen X. RNA virus-encoded microRNAs: biogenesis, functions and perspectives on application. ExRNA. 2020;2(1):15. DOI: 10.1186/s41544-020-00056-zBader A.G., Brown D., Stoudemire J., Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011;18:1121–6. DOI: 10.1038/gt.2011.79Bader A.G., Brown D., Stoudemire J., Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011;18:1121–6. DOI: 10.1038/gt.2011.79Lin K., Farahani M., Yang Y., Johnson G.G., Oates M., Atherton M., et al. Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. Br J Haematol. 2014;167(3):346–55. DOI: 10.1111/bjh.13043Lin K., Farahani M., Yang Y., Johnson G.G., Oates M., Atherton M., et al. Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. Br J Haematol. 2014;167(3):346–55. DOI: 10.1111/bjh.13043Svoronos A.A., Engelman D.M., Slack F.J. OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. Cancer Res. 2016;76(13):3666–70. DOI: 10.1158/0008-5472.CAN-16-0359Svoronos A.A., Engelman D.M., Slack F.J. OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. Cancer Res. 2016;76(13):3666–70. DOI: 10.1158/0008-5472.CAN-16-0359Paliouras A.R., Monteverde T., Garofalo M. Oncogene- induced regulation of microRNA expression: Implications for cancer initiation, progression and therapy. Cancer Lett. 2018;421:152–60. DOI: 10.1016/j.canlet.2018.02.029Paliouras A.R., Monteverde T., Garofalo M. Oncogene-induced regulation of microRNA expression: Implications for cancer initiation, progression and therapy. Cancer Lett. 2018;421:152–60. DOI: 10.1016/j.canlet.2018.02.029Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004. DOI: 10.1073/pnas.0307323101Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004. DOI: 10.1073/pnas.0307323101Piao Y., Piao M., Ryu K.H. Multiclass cancer classification using a feature subset-based ensemble from microRNA expression profiles. Comput Biol Med. 2017;80:39–44. DOI: 10.1016/j.compbiomed.2016.11.008Piao Y., Piao M., Ryu K.H. Multiclass cancer classification using a feature subset-based ensemble from microRNA expression profiles. Comput Biol Med. 2017;80:39–44. DOI: 10.1016/j.compbiomed.2016.11.008Yang Y., Mei Q. miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression. Mol Vis. 2015;21:1307–17. PMID: 26730174Yang Y., Mei Q. miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression. Mol Vis. 2015;21:1307–17. PMID: 26730174Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98. DOI: 10.1016/j.ccr.2006.01.025Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98. DOI: 10.1016/j.ccr.2006.01.025Pichler M., Winter E., Stotz M., Eberhard K., Samonigg H., Lax S., et al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer. 2012;106:1826–32. DOI: 10.1038/bjc.2012.175Pichler M., Winter E., Stotz M., Eberhard K., Samonigg H., Lax S., et al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer. 2012;106:1826–32. DOI: 10.1038/bjc.2012.175Zhi F., Chen X., Wang S., Xia X., Shi Y., Guan W., et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer. 2010;46:1640–9. DOI: 10.1016/j.ejca.2010.02.003Zhi F., Chen X., Wang S., Xia X., Shi Y., Guan W., et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer. 2010;46:1640–9. DOI: 10.1016/j.ejca.2010.02.003Giovannetti E., Funel N., Peters G.J., Del Chiaro M., Erozenci L.A., Vasile E., et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010;70:4528–38. DOI: 10.1158/0008-5472.CAN-09-4467Giovannetti E., Funel N., Peters G.J., Del Chiaro M., Erozenci L.A., Vasile E., et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010;70:4528–38. DOI: 10.1158/0008-5472.CAN-09-4467Komori T. The 2016 WHO classification of tumours of the central nervous system: the major points of revision. Neurol Med Chir (Tokyo). 2017;57(7):301–11. DOI: 10.2176/nmc.ra.2017-0010Komori T. The 2016 WHO classification of tumours of the central nervous system: the major points of revision. Neurol Med Chir (Tokyo). 2017;57(7):301–11. DOI: 10.2176/nmc.ra.2017-0010Ries L.A.G., Smith M.A., Gurney J.G., Linet M., Tamra T., Young J.L., et al. (eds). Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute: Bethesda; 1999.Ries L.A.G., Smith M.A., Gurney J.G., Linet M., Tamra T., Young J.L., et al. (eds). Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute: Bethesda; 1999.Casciati A., Tanori M., Manczak R., Saada S., Tanno B., Giardullo P., et al. Human medulloblastoma cell lines: investigating on cancer stem cell-like phenotype. Cancers (Basel). 2020;12(1):226. DOI: 10.3390/cancers12010226Casciati A., Tanori M., Manczak R., Saada S., Tanno B., Giardullo P., et al. Human medulloblastoma cell lines: investigating on cancer stem cell-like phenotype. Cancers (Basel). 2020;12(1):226. DOI: 10.3390/cancers12010226Thompson M.C., Fuller C., Hogg T.L., Dalton J., Finkelstein D., Lau C.C., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24:1924–31. DOI: 10.1200/JCO.2005.04.4974Thompson M.C., Fuller C., Hogg T.L., Dalton J., Finkelstein D., Lau C.C., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24:1924–31. DOI: 10.1200/JCO.2005.04.4974Kool M., Koster J., Bunt J., Hasselt N.E., Lakeman A., van Sluis P., et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3:e3088. DOI: 10.1371/journal.pone.0003088Kool M., Koster J., Bunt J., Hasselt N.E., Lakeman A., van Sluis P., et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3:e3088. DOI: 10.1371/journal.pone.0003088Northcott P.A., Korshunov A., Witt H., Hielscher T., Eberhart C.G., Mack S., et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29:1408–14. DOI: 10.1200/JCO.2009.27.4324Northcott P.A., Korshunov A., Witt H., Hielscher T., Eberhart C.G., Mack S., et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29:1408–14. DOI: 10.1200/JCO.2009.27.4324Remke M., Hielscher T., Korshunov A., Northcott P.A., Bender S., Kool M., et al. FSTL5 is a marker of poor prognosis in non-WNT/nonSHH medulloblastoma. J Clin Oncol. 2011;29:3852–61. DOI: 10.1200/JCO.2011.36.2798Remke M., Hielscher T., Korshunov A., Northcott P.A., Bender S., Kool M., et al. FSTL5 is a marker of poor prognosis in non-WNT/nonSHH medulloblastoma. J Clin Oncol. 2011;29:3852–61. DOI: 10.1200/JCO.2011.36.2798Taylor M.D., Northcott P.A., Korshunov A., Remke M., Cho Y.J., Clifford S.C., et al. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol. 2012;123:465–72. DOI: 10.1007/s00401-011-0922-zTaylor M.D., Northcott P.A., Korshunov A., Remke M., Cho Y.J., Clifford S.C., et al. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol. 2012;123:465–72. DOI: 10.1007/s00401-011-0922-zRemke M., Ramaswamy V., Taylor M.D. Medulloblastoma molecular dissection: The way toward targeted therapy. Curr Opin Oncol. 2013;25:674–81. DOI: 10.1097/CCO.0000000000000008Remke M., Ramaswamy V., Taylor M.D. Medulloblastoma molecular dissection: The way toward targeted therapy. Curr Opin Oncol. 2013;25:674–81. DOI: 10.1097/CCO.0000000000000008Vidal D.O., Marques M.M., Lopes L.F., Reis R.M. The role of microRNAs in medulloblastoma. J Pediatr Hematol Oncol. 2013;30:367–78. DOI: 10.3109/08880018.2013.783890Vidal D.O., Marques M.M., Lopes L.F., Reis R.M. The role of microRNAs in medulloblastoma. J Pediatr Hematol Oncol. 2013;30:367–78. DOI: 10.3109/08880018.2013.783890Cho Y.J., Tsherniak A., Tamayo P., Santagata S., Ligon A., Greulich H., et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29(11):1424–30. DOI: 10.1200/JCO.2010.28.5148Cho Y.J., Tsherniak A., Tamayo P., Santagata S., Ligon A., Greulich H., et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29(11):1424–30. DOI: 10.1200/JCO.2010.28.5148Northcott P.A., Fernandez L.A., Hagan J.P., Ellison D.W., Grajkowska W., Gillespie Y., et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res. 2009;69(8):3249–55. DOI: 10.1158/0008-5472.CAN-08-4710Northcott P.A., Fernandez L.A., Hagan J.P., Ellison D.W., Grajkowska W., Gillespie Y., et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res. 2009;69(8):3249–55. DOI: 10.1158/0008-5472.CAN-08-4710Murphy B.L., Obad S., Bihannic L., Ayrault O., Zindy F., Kauppinen S., et al. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res. 2013;73(23):7068–78. DOI: 10.1158/0008-5472.CAN-13-0927Murphy B.L., Obad S., Bihannic L., Ayrault O., Zindy F., Kauppinen S., et al. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res. 2013;73(23):7068–78. DOI: 10.1158/0008-5472.CAN-13-0927Zindy F., Kawauchi D., Lee Y., Ayrault O., Merzoug L.B., McKinnon P.J., et al. Role of the miR-17~92 cluster family in cerebellar and medulloblastoma development. Biol Open. 2014;3(7):597–605. DOI: 10.1242/bio.20146734Zindy F., Kawauchi D., Lee Y., Ayrault O., Merzoug L.B., McKinnon P.J., et al. Role of the miR-17~92 cluster family in cerebellar and medulloblastoma development. Biol Open. 2014;3(7):597–605. DOI: 10.1242/bio.20146734Pal R., Greene S. microRNA-10b is overexpressed and critical for cell survival and proliferation in medulloblastoma. Plos one. 2015;10(9):e0137845. DOI: 10.1371/journal.pone.0137845Pal R., Greene S. microRNA-10b is overexpressed and critical for cell survival and proliferation in medulloblastoma. Plos one. 2015;10(9):e0137845. DOI: 10.1371/journal.pone.0137845Grunder E., D’Ambrosio R., Fiaschetti G., Abela L., Arcaro A., Zuzak T., et al. MicroRNA-21 suppression impedes medulloblastoma cell migration. Eur J Cancer. 2011;47(16):2479–90. DOI: 10.1016/j.ejca.2011.06.041Grunder E., D’Ambrosio R., Fiaschetti G., Abela L., Arcaro A., Zuzak T., et al. MicroRNA-21 suppression impedes medulloblastoma cell migration. Eur J Cancer. 2011;47(16):2479–90. DOI: 10.1016/j.ejca.2011.06.041Weeraratne S.D., Amani V., Teider N., Pierre-Francois J., Winter D., Kye M.J., et al. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 2012;123(4):539–52. DOI: 10.1007/s00401-012-0969-5Weeraratne S.D., Amani V., Teider N., Pierre-Francois J., Winter D., Kye M.J., et al. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 2012;123(4):539–52. DOI: 10.1007/s00401-012-0969-5Bai A.H., Milde T., Remke M., Rolli C.G., Hielscher T., Cho Y.J., et al. MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol. 2012;123(4):529–38. DOI: 10.1007/s00401-011-0924-xBai A.H., Milde T., Remke M., Rolli C.G., Hielscher T., Cho Y.J., et al. MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol. 2012;123(4):529–38. DOI: 10.1007/s00401-011-0924-xZhang Z., Li S., Cheng S.Y. The miR-183~96~182 cluster promotes tumorigenesis in a mouse model of medulloblastoma. J Biomed Res. 2013;27(6):486–94. DOI: 10.7555/JBR.27.20130010Zhang Z., Li S., Cheng S.Y. The miR-183~96~182 cluster promotes tumorigenesis in a mouse model of medulloblastoma. J Biomed Res. 2013;27(6):486–94. DOI: 10.7555/JBR.27.20130010Weeraratne S.D., Amani V., Neiss A., Teider N., Scott D.K., Pomeroy S.L., et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2011;13:165–75. DOI: 10.1093/neuonc/noq179Weeraratne S.D., Amani V., Neiss A., Teider N., Scott D.K., Pomeroy S.L., et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2011;13:165–75. DOI: 10.1093/neuonc/noq179de Antonellis P., Medaglia C., Cusanelli E., Andolfo I., Liguori L., De Vita G., et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One. 2011;6:e24584. DOI: 10.1371/journal.pone.0024584de Antonellis P., Medaglia C., Cusanelli E., Andolfo I., Liguori L., De Vita G., et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One. 2011;6:e24584. DOI: 10.1371/journal.pone.0024584Pierson J., Hostager B., Fan R., Vibhakar R. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 2008;90:1–7. DOI: 10.1007/s11060-008-9624-3Pierson J., Hostager B., Fan R., Vibhakar R. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 2008;90:1–7. DOI: 10.1007/s11060-008-9624-3Li K.K., Pang J.C., Ching A.K., Wong C.K., Kong X., Wang Y., et al. miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. Hum Pathol. 2009;40:1234–43. DOI: 10.1016/j.humpath.2009.02.003Li K.K., Pang J.C., Ching A.K., Wong C.K., Kong X., Wang Y., et al. miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. Hum Pathol. 2009;40:1234–43. DOI: 10.1016/j.humpath.2009.02.003Ferretti E., De Smaele E., Miele E., Laneve P., Po A., Pelloni M., et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 2008;27:2616–27. DOI: 10.1038/emboj.2008.172Ferretti E., De Smaele E., Miele E., Laneve P., Po A., Pelloni M., et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 2008;27:2616–27. DOI: 10.1038/emboj.2008.172Venkataraman S., Alimova I., Fan R., Harris P., Foreman N., Vibhakar R. MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One. 2010;5:e10748. DOI:0. 1371/journal.pone.0010748Venkataraman S., Alimova I., Fan R., Harris P., Foreman N., Vibhakar R. MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One. 2010;5:e10748. DOI:0. 1371/journal.pone.0010748Gokhale A., Kunder R., Goel A., Sarin R., Moiyadi A., Shenoy A., et al. Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther. 2010;6:521–9. DOI: 10.4103/0973-1482.77072Gokhale A., Kunder R., Goel A., Sarin R., Moiyadi A., Shenoy A., et al. Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther. 2010;6:521–9. DOI: 10.4103/0973-1482.77072Garzia L., Andolfo I., Cusanelli E., Marino N., Petrosino G., De Martino D., et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One. 2009;4:e4998. DOI: 10.1371/journal.pone.0004998Garzia L., Andolfo I., Cusanelli E., Marino N., Petrosino G., De Martino D., et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One. 2009;4:e4998. DOI: 10.1371/journal.pone.0004998
The authors declare that there are no conflicts of interest present.